ClinicalTrials.gg
Not yet recruitingNCT07611162Updated May 28, 2026

Comparative Effectiveness of Alginate, Magaldrate, Sucralfate, Proton Pump Inhibitors, and Diet in Laryngopharyngeal Reflux Disease

A Phase 4 interventional study of Alginate and Magaldrate in Laryngopharyngeal Reflux Disease, sponsored by University of Mons. Not yet recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by University of Mons · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this randomized controlled trial is to compare the effectiveness of different treatments for laryngopharyngeal reflux disease (LPRD) in adult patients with confirmed symptoms and signs of the condition. The main question it aims to answer is:

Which treatment (Proton Pump Inhibitors (PPIs), alginate, magaldrate, sucralfate, or diet) leads to the greatest improvement in LPRD symptoms and clinical signs over 3 months? Researchers will compare proton pump inhibitors to alternative medical treatments and dietary management to see which approach is most effective and better tolerated.

Participants will:

  • undergo a clinical ENT examination with scoring of reflux signs (RSA)
  • complete symptom questionnaires (RSS) assessing severity, frequency, and impact of symptoms
  • receive one of the study treatments (medication or dietary intervention)
  • be evaluated at baseline and again after 3 months of treatment
02

Conditions studied

  • Laryngopharyngeal Reflux Disease
03

In context

Laryngopharyngeal Reflux

56 studies on the registry are indexed under Laryngopharyngeal Reflux; 8 are open to participants now.

This study's planned enrollment of 800 is above the median of 72 across 41 interventional studies indexed under Laryngopharyngeal Reflux.

Browse Laryngopharyngeal Reflux studies →

Lead sponsor

University of Mons is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Positive 24-h HEMII-pH > 1 event

Exclusion criteria

Exclusion Criteria:

  • Smoker (>5 cigarettes/day) , alcohol dependence (>3 units/day),
  • upper respiratory tract infection within the last month,
  • pregnancy,
  • neurological or psychiatric illness,
  • previous history of neck surgery or trauma,
  • ,
  • history of head and neck radiotherapy
  • active seasonal allergies or asthma.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Active comparator
    Alginate

    Drug: Alginate

  • Active comparator
    Magaldrate

    Drug: Magaldrate

  • Active comparator
    Proton pump inhibitors

    Drug: Proton Pump Inhibitor (PPI) Therapy

  • Active comparator
    Sucralfate

    Drug: Sucralfate

  • Active comparator
    Anti-reflux diet

    Behavioral: Diet

Interventions

  • DrugAlginate

    Drug pages: AlginatesStudies of AlginatesAlginates pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Alginic AcidStudies of Alginic AcidAlginic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Use of Gaviscon anti-acid, anti-reflux

  • DrugMagaldrate

    use of Riopan drug

  • use of Kéal sucralfate

  • DrugProton Pump Inhibitor (PPI) Therapy

    Use of Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole

  • BehavioralDiet

    Patients are recommended to adhere to a 3-month low-fat, low quick-release sugar, high-protein, alkaline, and plant-based diet. The consumption of fish and meat was authorized but reduced to low-fat fish and meat. The anti-reflux diet considered the exclusion/reduction of additional triggers such as caffeine or theine, spices, tomatoes, fatty, cheese alcohol, and sparkling beverages.

06

What researchers measure

Primary outcomes

  1. Comparison of the effectiveness of each intervention based on changes in Reflux Symptom Score (RSS) and Reflux Sign Assessment (RSA) from pre- to post-treatment follow-up.

    Time frame: From enrollment to the end of treatment at 3 months

07

Study locations

1 site
  • University of Mons
    Mons, 7000, Belgium
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for May 2030, 48 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
May 28, 2026
StartEst.
May 1, 2026
Primary completionEst.
May 1, 2030
CompletionEst.
May 1, 2030
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07611162
Lead sponsor
University of Mons
Responsible party
Jerome lechien (Chairman & Professor of General Surgery, University of Mons) — Principal investigator
First posted
May 28, 2026
Start date
May 1, 2026 (estimated)
Primary completion
May 1, 2030 (estimated)
Completion
May 1, 2030 (estimated)
Last update
May 28, 2026

Study contacts

Jérome R Lechien, MD, PhD, MS, FACS
Contact
jerome.lechien@umons.ac.be
+32 498 64 09 19

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alginates · Alginic Acid · Sucralfate

Start the discussion